NO793297L - PROCEDURE FOR THE MANUFACTURE OF OXYMORPHONE - Google Patents
PROCEDURE FOR THE MANUFACTURE OF OXYMORPHONEInfo
- Publication number
- NO793297L NO793297L NO793297A NO793297A NO793297L NO 793297 L NO793297 L NO 793297L NO 793297 A NO793297 A NO 793297A NO 793297 A NO793297 A NO 793297A NO 793297 L NO793297 L NO 793297L
- Authority
- NO
- Norway
- Prior art keywords
- demethylating
- boron
- approx
- amount
- boron compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 34
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 title claims description 27
- 229960005118 oxymorphone Drugs 0.000 title claims description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 31
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 30
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 230000001335 demethylating effect Effects 0.000 claims description 26
- 229960002085 oxycodone Drugs 0.000 claims description 26
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 150000001639 boron compounds Chemical class 0.000 claims description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 239000012429 reaction media Substances 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 17
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 16
- 230000007062 hydrolysis Effects 0.000 claims description 16
- 239000012649 demethylating agent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000006227 byproduct Substances 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 claims description 7
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010520 demethylation reaction Methods 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000002879 Lewis base Substances 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 150000007527 lewis bases Chemical class 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000010410 layer Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 from 5 to 20% Chemical compound 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Polarising Elements (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte for fremstilling av oksymorfon. Process for the production of oxymorphone.
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av oksy morfon. The present invention relates to a method for the production of oxymorphone.
Oksymorfon er et narkotisk stoff og er meget anvendt som smertestillende middel. Den mest anvendte fremgangsmåten for fremstilling av oksymorfon er beskrevet av Seki, Takamine Kenkyisho Nempo, 12, 52 (1960). Den inbefatter at man omsetter pyridinhydroklorid med oksykodon ved høye temperaturer. Denne fremgangsmåten har ulemper når den skal anvendes på kommersiellskala, fordi reaksjonen er vanskelig å regulere, Oxymorphone is a narcotic drug and is widely used as a pain reliever. The most widely used method for the preparation of oxymorphone is described by Seki, Takamine Kenkyisho Nempo, 12, 52 (1960). It involves reacting pyridine hydrochloride with oxycodone at high temperatures. This method has disadvantages when it is to be used on a commercial scale, because the reaction is difficult to regulate,
og det trengs høye temperaturer. Videre vil man ved reaksjonen bare få moderate utbytter av det forønskede stoff, foruten at det dannes betydelige mengder av biprodukter. and high temperatures are needed. Furthermore, only moderate yields of the desired substance will be obtained in the reaction, in addition to the formation of significant amounts of by-products.
Det er en hensikt ved foreliggende oppfinnelseIt is a purpose of the present invention
å tilveiebringe en fremgangsmåte for fremstilling av oksymorfon i godt utbytte og hvor det i alt vesentlig ikke dannes noen biprodukter. to provide a method for producing oxymorphone in good yield and where essentially no by-products are formed.
Det er videre en hensikt ved foreliggende oppfinnelse å selektivt demetylere oksykodonmetoksygruppen uten at man påvirker andre posisjoner i oksykodonmolekylet hvor eterbindinger eventuelt kan spaltes. It is also a purpose of the present invention to selectively demethylate the oxycodone methoxy group without affecting other positions in the oxycodone molecule where ether bonds can possibly be cleaved.
Foreliggende oppfinnelse tilveiebringer så-ledes en fremgangsmåte for fremstilling av oksymorfon ved at man selektivt fjerner metylgruppen fra metoksygruppen i oksykodon, og hvor fremgangsmåten inbefatter at man reagerer sistnevnte forbindelse med en demetylert mengde av et demetyleringsmiddel under demetylerende betingelser i nærvær av en dempende mengde av et dempingsmiddel for å dempe aktiviteten på demetyleringsmidlet, hvorved oksymorfon fremstilles i godt utbytte og i alt vesentlig uten biprodukter. The present invention thus provides a method for the production of oxymorphone by selectively removing the methyl group from the methoxy group in oxycodone, and wherein the method includes reacting the latter compound with a demethylated amount of a demethylating agent under demethylating conditions in the presence of an attenuating amount of a dampening agent to dampen the activity of the demethylating agent, whereby oxymorphone is produced in good yield and essentially without by-products.
Egnede demetyleringsmidler er borforbindelser som er i stand til å demetylere metoksygruppen, men som ikke er istand til å danne tallrike biprodukter. Slike borforbindelser inbefatter bortribromid, bortriklorid eller reaksjonsproduktet av slike halogenider med alkoholer, f.eks. de som inneholder fra 1 til 10 karbonatomer, fortrinnsvis laverealkoholer, med fra 1 til 6 karbonatomer, f.eks. metanol, propanol, butanol, heksanol, etc. Suitable demethylating agents are boron compounds which are capable of demethylating the methoxy group, but which are not capable of forming numerous by-products. Such boron compounds include boron tribromide, boron trichloride or the reaction product of such halides with alcohols, e.g. those containing from 1 to 10 carbon atoms, preferably lower alcohols, with from 1 to 6 carbon atoms, e.g. methanol, propanol, butanol, hexanol, etc.
Tilstede i reaksjonsmediet under den nevnte demetyleringsreaksjon er et dempende middel for å dempe aktiviteten på borforbindelsen slik at når denne brukes i foreliggende fremgangsmåte, så får man godt utbytte av oksymorfon og i alt vesentlig ingen biprodukter. Det dempende middel kan være en svak Lewis-base som ikke kjemisk reagerer med demetyleringsmidlet. Dempningsmidlet inbefatter normalt flytende, aromatisk oppløsningsmiddel som ikke kjemisk reagerer med borforbindelsen, man kan f.eks. bruke benzen, toluen, xylen, etylbenzen, nitrobenzen, klorbenzen, difenyleter og blandinger av disse. Klorbenzen er det foretrukne dempningsmiddel. Dempende mengder inbefatter fra 25 til 900 vektsprosent basert .på vekten av borforbindelsen. Present in the reaction medium during the aforementioned demethylation reaction is a dampening agent to dampen the activity of the boron compound so that when this is used in the present method, a good yield of oxymorphone is obtained and essentially no by-products. The quenching agent may be a weak Lewis base that does not chemically react with the demethylating agent. The dampening agent normally includes a liquid, aromatic solvent which does not chemically react with the boron compound, one can e.g. use benzene, toluene, xylene, ethylbenzene, nitrobenzene, chlorobenzene, diphenyl ether and mixtures of these. Chlorobenzene is the dampening agent of choice. Attenuating amounts include from 25 to 900 weight percent based on the weight of the boron compound.
Det er foretrukket å bruke en demetylerende sammensetning som inneholder en borforbindelse i en mengde som er tilstrekkelig til å demetylere metoksygruppen i oksykodon, f.eks. fra 5 til 20%, fortrinnsvis ca. 10% basert på It is preferred to use a demethylating composition containing a boron compound in an amount sufficient to demethylate the methoxy group in oxycodone, e.g. from 5 to 20%, preferably approx. 10% based on
den totale vekt av den nevnte demetylerende sammensetningen,the total weight of said demethylating composition,
samt en dempende mengde av et dempningsmiddel, f.eks. fra 80 til 95%, fortrinnsvis ca. 90 vektsprosent, basert på den totale vekt av den demetylerende sammensetningen. as well as a dampening amount of a dampening agent, e.g. from 80 to 95%, preferably approx. 90% by weight, based on the total weight of the demethylating composition.
Oksymorfon reageres med forannevnte demetyleringsmiddel under demetylerende betingelser. Dette inbefatter at man bruker en demetylerende mengde av et demetyleringsmiddel, f.eks. Oxymorphone is reacted with the aforementioned demethylating agent under demethylating conditions. This includes using a demethylating amount of a demethylating agent, e.g.
i form av bortrihalogenid, hvor man anvender fra 2 til 8 mol, fortrinnsvis 2,5 til 3,5 mol, mere foretrukket fra 2,5 til 7 in the form of boron trihalide, using from 2 to 8 mol, preferably 2.5 to 3.5 mol, more preferably from 2.5 to 7
mol, av borforbindelsen pr. mol av oksykodon. Man oppnår ingen betydelig fordel ved å bruke mere enn 8 mol, skjønt dette er mulig. Bruker man mindre enn ca. 2 mol, så får man en ufullstendig reaksjon. Andre demetylerende betingelser inbefatter egnede reaksjonstider, d.v.s. fra 8 til 24 timer og temperaturer fra 0 til 40°C. Som nevnt foran er det foretrukket å reagere oksykodon med forannevnte demetylerende sammensetning. Normalt mol, of the boron compound per moles of oxycodone. No significant advantage is gained by using more than 8 moles, although this is possible. If you use less than approx. 2 mol, then you get an incomplete reaction. Other demethylating conditions include suitable reaction times, i.e. from 8 to 24 hours and temperatures from 0 to 40°C. As mentioned above, it is preferred to react oxycodone with the aforementioned demethylating composition. Normally
vil denne sammensetningen være tilstrekkelig flytende til at det ikke er nødvendig å bruke ytterligere oppløsningsmiddel for å få gjennomført reaksjonen. Det kan imidlertid være fordelaktig å tilsette et oppløsningsmiddel, f.eks. et inert oppløsningsmiddel, som ikke vil reagere med borforbindelsen, f.eks. klorbenzen. Et slikt oppløsningsmiddel er fortrinnsvis det samme, men kan være forskjellig fra det anvendte dempningsmiddel . this composition will be sufficiently liquid that it is not necessary to use additional solvent to carry out the reaction. However, it may be advantageous to add a solvent, e.g. an inert solvent, which will not react with the boron compound, e.g. chlorobenzene. Such a solvent is preferably the same, but may be different from the dampening agent used.
Alternativt kan demetyleringsmidlet tilsettes reaksjonsmediet separat forutsatt at det dempende middel er tilstede i tilstrekkelig mengde til å dempe aktiviteten på demetyleringsmidlet. F. eks. kan oksykodon blandes med dempningsmidlet som så tilsettes demetyleringsmidlet. Alternatively, the demethylating agent may be added to the reaction medium separately provided that the dampening agent is present in sufficient quantity to dampen the activity of the demethylating agent. For example oxycodone can be mixed with the suppressant to which the demethylating agent is added.
Etterat oksykodon dem etyleringen er utførtAfter the oxycodone dem ethylation is done
i så høy grad som ønskelig, kan demetyleringsreaksjonen stanses ved at reaksjonsmediet tilsettes vann. Fortrinnsvis bør vann tilsettes i en mengde som er lik eller større enn volumet på det vannfrie reaksjonsmediet. to the extent desired, the demethylation reaction can be stopped by adding water to the reaction medium. Preferably, water should be added in an amount equal to or greater than the volume of the anhydrous reaction medium.
For å få maksimalt utbytte av oksymorfonTo get the maximum benefit from oxymorphone
kan reaksjonsblandingen deretter med fordel hydrolyseres i et visst tidsrom.og under slike hydrolysebetingelser at man kan øke den mengde av innvinnbart oksymorfon som er til- the reaction mixture can then advantageously be hydrolysed for a certain period of time and under such hydrolysis conditions that the amount of recoverable oxymorphone that is available can be increased
stede i reaksjonsmediet. Hydrolysen tjener til å hydrolysere både overskudd av reaktanter og reaksjonsprodukter som måtte være tilstede i reaksjonsmediet etter demetyleringen. Egnede hydrolysereaksjonstider inbefatter fra en 1/2 til present in the reaction medium. The hydrolysis serves to hydrolyze both excess reactants and reaction products that may be present in the reaction medium after the demethylation. Suitable hydrolysis reaction times include from a 1/2 to
10 timer, fortrinnsvis 2 til 4 timer. Egnede temperaturer for denne hydrolysen varierer fra 60 til 120°C, fortrinnsvis 80 - 100°C. Man har funnet at en hydrolyse av reaksjonsblandingen ved høyere temperaturer, f.eks. ved koking med tilbakeløp er spesielt fordelaktig, spesielt når man bruker klorbenzen som dempende middel og oppløsningsmiddel. Uten å være bundet av en eller flere spesielle teorier, så antar man at hydrolysen ved høyere temperaturer fremmer hydrolyse av de reaksjonsprodukter som er i form av borkomplekset, f. eks. komplekser som inneholder en bor- nitrogenbinding, hvorved man omdanner mer av slike komplekser til innvinnbart oksomorfon. Høyere hydrolysetemperaturer tjener også til omdannelse av andre biprodukter som måtte være tilstede i blandingen til et innvinnbart produkt. . ^ , . EttSr h^drolysen ble pH på reaksjonsblandingen istert txl ca. 4,5 til 6 med syre, f.eks. saltsyre eller svovelsyre, ble så filtrert og justert med en egnet baée, 10 hours, preferably 2 to 4 hours. Suitable temperatures for this hydrolysis range from 60 to 120°C, preferably 80 to 100°C. It has been found that a hydrolysis of the reaction mixture at higher temperatures, e.g. under reflux is particularly advantageous, especially when using chlorobenzene as a quencher and solvent. Without being bound by one or more particular theories, it is assumed that the hydrolysis at higher temperatures promotes hydrolysis of the reaction products that are in the form of the boron complex, e.g. complexes containing a boron-nitrogen bond, whereby more of such complexes are converted into recoverable oxomorphone. Higher hydrolysis temperatures also serve to convert other by-products that may be present in the mixture into a recoverable product. . ^ , . After the hydrolysis, the pH of the reaction mixture was adjusted to approx. 4.5 to 6 with acid, e.g. hydrochloric or sulfuric acid, was then filtered and adjusted with a suitable baée,
f.eks. natriumhydroksyd, til en pH mellom 10 og 12 og så ekstrahert med ett av de vanlige kjente inerte organiske ekstraksjonsmidler, f.eks. toluen. Det vandige lag ble sa justert til en pH ca. 2 med syre og så til ca. 8,5 med base, og igjen ekstrahertover i inert organisk oppløsninga--ddel, f.eks. metylenklorid, som så ble fordampet hvorved man far oksymorfon i alt vesentlig fritt for urenheter. Det første organiske ekstrakt blir fordampet, hvorved man får oksykodon som egnet kan brukes for resirkulering. e.g. sodium hydroxide, to a pH between 10 and 12 and then extracted with one of the usual known inert organic extractants, e.g. toluene. The aqueous layer was thus adjusted to a pH of approx. 2 with acid and then until approx. 8.5 with base, and again extracted into inert organic solution part, e.g. methylene chloride, which was then evaporated, thereby obtaining oxymorphone essentially free of impurities. The first organic extract is evaporated, whereby oxycodone is obtained which can be used for recycling.
_De følgende eksempler illustrerer oppfinnelsen. Alle deler er pr. vekt hvis intet annet er angitt. _The following examples illustrate the invention. All parts are per weight unless otherwise stated.
Eksempel 1Example 1
En suspensjon av 25 g oksykodonbase i 200 ml klorbenzen ble tilsatt i et kar med tilstrekkelig røreutstyr og innholdet ble avkjølt til mindre enn 10°C. En oppløsning på 60 g bortribromid ble fremstillet i 200 ml klorbenzen og denne oppløsningen ble i løpet av 5 minutter tilsatt oksykodon-suspensjonen. Temperaturen stiger til ca. 35°C. Kjølingen ble fjernet, og blandingen ble rørt i 18 timer. Blandingen ble så helt over i 250 ml vann og deretter kokt under tilbakeløp i 2 timer. De vandige og organiske lag ble adskilt og det vandige lag ble undersøkt for oksykodon og oksymorfon. Det vandige lag ble justert til pH 5,5 med natriumhydroksyd eller ammoniakk og så filtrert. Filtratet ble justert til en pH 12 med natriumhydroksyd og så ekstrahert med metylenklorid. Metylenkloridlaget ble utskilt og fordampet, hvorved man fikk oksykodon som kan recykleres. Det vandige lag ble surgjort med saltsyre til en pH på 2,0 og så justert til pH 8,5 med ammoniakk og så igjen ekstrahert med metylenklorid. Det organiske lag ble fordampet og man fikk i alt vesentlig ren oksymorfon. A suspension of 25 g of oxycodone base in 200 ml of chlorobenzene was added to a vessel with adequate stirring equipment and the contents were cooled to less than 10°C. A solution of 60 g of boron tribromide was prepared in 200 ml of chlorobenzene and this solution was added to the oxycodone suspension within 5 minutes. The temperature rises to approx. 35°C. The cooling was removed and the mixture was stirred for 18 hours. The mixture was then poured into 250 ml of water and then boiled under reflux for 2 hours. The aqueous and organic layers were separated and the aqueous layer was examined for oxycodone and oxymorphone. The aqueous layer was adjusted to pH 5.5 with sodium hydroxide or ammonia and then filtered. The filtrate was adjusted to a pH of 12 with sodium hydroxide and then extracted with methylene chloride. The methylene chloride layer was separated and evaporated, yielding oxycodone which can be recycled. The aqueous layer was acidified with hydrochloric acid to a pH of 2.0 and then adjusted to pH 8.5 with ammonia and then again extracted with methylene chloride. The organic layer was evaporated and essentially pure oxymorphone was obtained.
Data for dette eksperiment er vist i den følg-ende tabell I, såvel som det man fikk for andre oppløsningsmidler idet man brukte i alt vesentlig den samme fremgangsmåten. Data for this experiment are shown in the following Table I, as well as that obtained for other solvents using essentially the same procedure.
Eksempel 2 Example 2
En suspensjon av 1,5 g oksykodon i benzen ble på en gang behandlet med 2,3 g bortribromid i benzen og blandingen ble rørt i 2 timer og deretter hydrolysert med et tilsvarende volum vann med koking under tilbakeløp i 2 timer. Det vandige lag ble undersøkt og man fant at det inneholdt 85% utbytte av oksymorfon og 15 % utbytte av oksykodon. A suspension of 1.5 g of oxycodone in benzene was treated at once with 2.3 g of boron tribromide in benzene and the mixture was stirred for 2 hours and then hydrolyzed with an equal volume of water at reflux for 2 hours. The aqueous layer was examined and found to contain 85% yield of oxymorphone and 15% yield of oxycodone.
Ved i det alt vesentlige å bruke samme fremgangsmåte som i eksempel 1 oppnådde man de data som er angitt i tabell II. By essentially using the same method as in example 1, the data set out in table II was obtained.
Eksempel 3 Example 3
Ved å bruke følgende generelle fremgangsmåte ble oksykodon demetylert til oksymorfon ved å bruke bortribromid som demetyleringsmiddel. Variasjoner med hensyn til forholdet mellom bortribromid og oksykodon, type av reaksjonsmediet anvendt organisk oppløsningsmiddel og hydrolysebetingelser er angitt i tabell III. Bortribromid i oppløsningsmiddel ble tilsatt en suspensjon av oksykodon i oppløsningsmiddel i forsøk 5-8, mens reaksjonsmediums temperaturen ble holdt under 10°C. Rekkefølgen med hensyn til tilsetning ble snudd opp ned Using the following general procedure, oxycodone was demethylated to oxymorphone using boron tribromide as the demethylating agent. Variations with regard to the ratio between boron tribromide and oxycodone, type of reaction medium used organic solvent and hydrolysis conditions are indicated in Table III. Boron tribromide in solvent was added to a suspension of oxycodone in solvent in experiments 5-8, while the temperature of the reaction medium was kept below 10°C. The order of addition was reversed
i forsøkene 1 til 4. Etter reaksjonstider fra 1 til 20 timer ble reaksjonen stoppet ved tilsetning av vann. Hydrolyse av reaksjonsblandingen finner enten sted ved 40°C eller ved koking ved tilbakeløp. pH i blanding ble så justert til ca. in experiments 1 to 4. After reaction times of 1 to 20 hours, the reaction was stopped by the addition of water. Hydrolysis of the reaction mixture takes place either at 40°C or by boiling at reflux. The pH in the mixture was then adjusted to approx.
5,5, og reaksjonsblandingen ble analysert for oksymorfon-omdannelse ved å bruke væskekromatografi teknikk. 5.5, and the reaction mixture was analyzed for oxymorphone conversion using a liquid chromatography technique.
Den ovennevnte tabell III viser klart at The above Table III clearly shows that
utbyttet av oksymorfon økes ved å bruke klorbenzen som et oppløsningsmiddel og dempningsmiddel, og ved å bruke varme hydrolysebetingelser. the yield of oxymorphone is increased by using chlorobenzene as a solvent and quencher, and by using hot hydrolysis conditions.
Eksempel 4Example 4
Ca 2,68 kg oksykodon ble tilsatt et reaksjons-?kar på 189 liter utstyrt med en varme/ kjølekappe, og nevnte kar inneholdt også 48 kg klorbenzen. Innholdet i karet ble raskt rørt og systemet renset med nitrogen. Ca. 7,8 kg bortribromid ble tilsatt blandingen i løpet av 20 til 30 About 2.68 kg of oxycodone was added to a reaction vessel of 189 liters equipped with a heating/cooling jacket, and said vessel also contained 48 kg of chlorobenzene. The contents of the vessel were quickly stirred and the system purged with nitrogen. About. 7.8 kg of boron tribromide was added to the mixture over 20 to 30
minutter og temperaturen på mediet ble holdt under 25°C.minutes and the temperature of the medium was kept below 25°C.
Etter bortribromidtilsetningen ble innholdetAfter the boron tribromide addition, the content became
rørt i 6 timer ved 25 til 28°C. På dette punkt ble reaksjonsblandingen pumpet til et kar på 246 liter og som inneholdt 32,66 kg vann som var avkjølt til mindre enn 10°C. Tilsetningen skjer slik at kartemperaturen holder seg under 30°C. stirred for 6 hours at 25 to 28°C. At this point the reaction mixture was pumped into a 246 liter vessel containing 32.66 kg of water which had been cooled to less than 10°C. The addition takes place so that the vessel temperature remains below 30°C.
Den resulterende blandingen blir pumpet tilbake til reaksjonskaret på 189 liter og oppvarmet med koking tilbakeløp (96°C) under langsom røring for å hindre en emulsjonsdannelse. Etter to timers koking med tilbakeløp ble innholdet i reaksjonskaret avkjølt til 60 til 80°C og lagene ble hensatt for adskillelse. Etter separasjonen ble bunnlaget som var det vandige lag fjernet, og det organiske lag ble renset med 5,67 kg de-ionisert vann under langsom røring. Ved hensetting av blandingen bytter lagene plass slik at det vandige lag nå blir topplaget. Dette ble fjernet og slått sammen med den tidligere vandige ekstraksjons-blandingen . The resulting mixture is pumped back to the 189 liter reaction vessel and heated at reflux (96°C) with slow stirring to prevent emulsion formation. After two hours of reflux, the contents of the reaction vessel were cooled to 60 to 80°C and the layers were set aside for separation. After the separation, the bottom layer which was the aqueous layer was removed, and the organic layer was cleaned with 5.67 kg of de-ionized water under slow stirring. When the mixture is set aside, the layers switch places so that the aqueous layer now becomes the top layer. This was removed and combined with the previous aqueous extraction mixture.
pH i det organiske lag ble justert til 5,5-6,0 med ammoniumhydroksyd. Ca 0,45-0,9 kg darko (aktivert karbon, Darco G-60) ble tilsatt, og blandingen ble filtrert og vasket med fra 3,8-7,6 liter de-ionisert vann. pH ble igjen justert til 8,8-8,9 med ammoniumhydroksyd. Den vandige suspensjonen ble ekstrahert med diklormetan i en kontinuerlig karr kolonne ekstraktor inntil den vandige delen inneholdt mindre enn 1,5 mg oksymorfon pr. ml. Diklormetandelen ble vasket tilbake med 2 3,8 liters porsjoner av de-ionisert vann og returnert til nevnte reaksjonskar på 189 liter og temperaturen ble holdt på 70-80°C. Diklormetanoppløsningen ble destillert til tørrhet, og den siste delen av diklormetanen og gjenværende vann ble fjernet The pH in the organic layer was adjusted to 5.5-6.0 with ammonium hydroxide. About 0.45-0.9 kg of darko (activated carbon, Darco G-60) was added, and the mixture was filtered and washed with from 3.8-7.6 liters of de-ionized water. The pH was again adjusted to 8.8-8.9 with ammonium hydroxide. The aqueous suspension was extracted with dichloromethane in a continuous vessel column extractor until the aqueous portion contained less than 1.5 mg of oxymorphone per ml. The dichloromethane portion was washed back with 2 3.8 liter portions of de-ionized water and returned to said reaction vessel of 189 liters and the temperature was maintained at 70-80°C. The dichloromethane solution was distilled to dryness and the last portion of the dichloromethane and remaining water was removed
under vakuum. Ca.30 liter vannfri etanol ble tilsatt reaksjonskaret og blandingen ble holdt på 65-70°C. Blandingen ble så filtrert hvis dette var nødvendig, og etanolblandingen ble så avkjølt under røring til under 10°C. Det resulterende krystalli-sasjonsproduktet ble frafiltrert og tørket ved 65-70°C fra 2-4 timer, og man fikk fra 1,36 - 1,59 kg oksymorfon. under vacuum. About 30 liters of anhydrous ethanol were added to the reaction vessel and the mixture was kept at 65-70°C. The mixture was then filtered if necessary and the ethanol mixture was then cooled with stirring to below 10°C. The resulting crystallization product was filtered off and dried at 65-70°C from 2-4 hours, and 1.36-1.59 kg of oxymorphone was obtained.
Filtratet ble fordampet til nesten tørrhet og er-stattet med 7,57 liter de-ionisert vann. pH ble justert til mindre enn 5,0 og så igjen justert til 8,5 til 8,8 med ammoniumhydroksyd, mens temperaturen ble holdt på under 30°C. Blandingen ble avkjølt til 10-15°C og det utfelte faste stoff The filtrate was evaporated to near dryness and replaced with 7.57 liters of deionized water. The pH was adjusted to less than 5.0 and then again adjusted to 8.5 to 8.8 with ammonium hydroxide while maintaining the temperature below 30°C. The mixture was cooled to 10-15°C and a solid precipitated
ble filtrert og vasket med to 0,95 liters porsjoner av vann ved 10-15°C. Det stoffet ble så tørket ved 70-80°C i minimum 6 timer, og man fikk 0,36 til 0,5 kg residuum av ytterligere oksymorfon-holdig produkt. was filtered and washed with two 0.95 liter portions of water at 10-15°C. That substance was then dried at 70-80°C for a minimum of 6 hours, and 0.36 to 0.5 kg residue of further oxymorphone-containing product was obtained.
Claims (22)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95305678A | 1978-10-19 | 1978-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO793297L true NO793297L (en) | 1980-04-22 |
Family
ID=25493512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO793297A NO793297L (en) | 1978-10-19 | 1979-10-12 | PROCEDURE FOR THE MANUFACTURE OF OXYMORPHONE |
Country Status (16)
Country | Link |
---|---|
JP (1) | JPS55501025A (en) |
AU (1) | AU5189779A (en) |
BE (1) | BE879494A (en) |
CA (1) | CA1108132A (en) |
CS (1) | CS211364B2 (en) |
DK (1) | DK258280A (en) |
ES (1) | ES485154A1 (en) |
FI (1) | FI793235A (en) |
FR (1) | FR2439201A1 (en) |
GB (1) | GB2049680A (en) |
IL (1) | IL58489A0 (en) |
IT (1) | IT7969032A0 (en) |
NL (1) | NL7920126A (en) |
NO (1) | NO793297L (en) |
SE (1) | SE8004454L (en) |
WO (1) | WO1980000841A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795813A (en) * | 1981-08-17 | 1989-01-03 | The Florida Board Of Regents On Behalf Of The Florida State University | Synthesis of derivatives of codeine and other 3-O-alkylmorphines |
US5668285A (en) * | 1986-10-31 | 1997-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates |
FR2636330B1 (en) * | 1988-09-13 | 1990-11-30 | Sanofi Sa | PROCESS FOR THE PREPARATION OF MORPHINANE DERIVATIVES |
AU642447B2 (en) * | 1989-10-16 | 1993-10-21 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via N-nor intermediates |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
BR0205721A (en) | 2001-07-06 | 2003-09-30 | Endo Pharmaceuticals Inc | Controlled Release Oxymorphone Formulations |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE602007003197D1 (en) | 2006-03-02 | 2009-12-24 | Mallinckrodt Inc | PROCESS FOR PREPARING MORPHINAN 6-ON PRODUCTS WITH LOW CONCENTRATIONS OF ALPHA, BETA-UNSATURATED KETONE COMPOUNDS |
NZ586792A (en) | 2008-01-25 | 2012-09-28 | Gruenenthal Chemie | Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces |
RU2508092C2 (en) | 2008-05-09 | 2014-02-27 | Грюненталь Гмбх | Method for preparing solid dosage form, particularly tablet for pharmaceutical application and method for preparing solid dosage form precursor, particularly tablet |
CN102573805A (en) | 2009-07-22 | 2012-07-11 | 格吕伦塔尔有限公司 | Hot-melt extruded controlled release dosage form |
WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
RU2607499C2 (en) | 2010-09-02 | 2017-01-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing anionic polymer |
PL2611426T3 (en) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
BR112014002022A2 (en) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | tamper-resistant tablet providing immediate drug release |
PT2736497T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
WO2015004245A1 (en) | 2013-07-12 | 2015-01-15 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CN105934241B (en) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | Preparation of powdered pharmaceutical composition by cryogenic grinding |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
MX2017013637A (en) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction. |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3252055B1 (en) | 2016-05-31 | 2018-09-19 | Alcaliber Investigacion Desarrollo e Innovacion SLU | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3249616A (en) * | 1966-05-03 | Ix-dfflydroxy-g-oxo-n-phenethylmor- phinan (cis) and production thereof | ||
US2806033A (en) * | 1955-08-03 | 1957-09-10 | Lewenstein | Morphine derivative |
US3775414A (en) * | 1972-05-10 | 1973-11-27 | Bristol Myers Co | Process for the preparation of 14-hydroxymorphinan derivatives |
-
1979
- 1979-10-12 NO NO793297A patent/NO793297L/en unknown
- 1979-10-18 IT IT7969032A patent/IT7969032A0/en unknown
- 1979-10-18 CA CA337,908A patent/CA1108132A/en not_active Expired
- 1979-10-18 ES ES485154A patent/ES485154A1/en not_active Expired
- 1979-10-18 FI FI793235A patent/FI793235A/en not_active Application Discontinuation
- 1979-10-18 IL IL58489A patent/IL58489A0/en unknown
- 1979-10-18 GB GB8014422A patent/GB2049680A/en not_active Withdrawn
- 1979-10-18 JP JP50190279A patent/JPS55501025A/ja active Pending
- 1979-10-18 NL NL7920126A patent/NL7920126A/en unknown
- 1979-10-18 WO PCT/US1979/000862 patent/WO1980000841A1/en unknown
- 1979-10-18 AU AU51897/79A patent/AU5189779A/en not_active Abandoned
- 1979-10-18 BE BE0/197710A patent/BE879494A/en unknown
- 1979-10-18 FR FR7925895A patent/FR2439201A1/en not_active Withdrawn
- 1979-10-19 CS CS797115A patent/CS211364B2/en unknown
-
1980
- 1980-06-16 SE SE8004454A patent/SE8004454L/en not_active Application Discontinuation
- 1980-06-17 DK DK258280A patent/DK258280A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU5189779A (en) | 1980-04-24 |
GB2049680A (en) | 1980-12-31 |
DK258280A (en) | 1980-06-17 |
IT7969032A0 (en) | 1979-10-18 |
WO1980000841A1 (en) | 1980-05-01 |
NL7920126A (en) | 1980-08-29 |
CS211364B2 (en) | 1982-02-26 |
ES485154A1 (en) | 1980-06-16 |
BE879494A (en) | 1980-02-15 |
JPS55501025A (en) | 1980-11-27 |
FR2439201A1 (en) | 1980-05-16 |
SE8004454L (en) | 1980-06-16 |
IL58489A0 (en) | 1980-01-31 |
FI793235A (en) | 1980-04-20 |
CA1108132A (en) | 1981-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO793297L (en) | PROCEDURE FOR THE MANUFACTURE OF OXYMORPHONE | |
US4521633A (en) | Bromination process | |
US3933852A (en) | Process for making N-methyl nitrophthalimides | |
US2107650A (en) | Preparation of pentachlorophenol | |
US6049014A (en) | Process for the manufacture of tetrabromobisphenol-A with co-production of n-propyl bromide | |
JP4049534B2 (en) | Process for producing O-alkyl-N-cyanoacetimidate | |
EP1041080B1 (en) | Process for the preparation of pentaacetyl-beta-D-glucopyranose | |
JPS6334856B2 (en) | ||
Coumbarides et al. | Investigations into the bromination of substituted phenols using diethyl bromomalonate and diethyl dibromomalonate | |
EP0148145B1 (en) | Process for making nitrodiarylamines | |
US2425283A (en) | Preparation of allylglycine | |
NO137093B (en) | PROCEDURES FOR THE PREPARATION OF 2,4-DIAMINO-5-BENZYLPYRIMIDINES | |
JPH02149586A (en) | Production of aryl metaborate and use thereof for production of 0-hydroxybenzyl alcohol | |
Marsili et al. | Reactions of 3, 4-disubstituted 4-oxazolin-2-ones. III. Reaction of 3, 4-diphenyl-4-oxazolin-2-one with organic nitrites | |
CA1134839A (en) | Preparation of 5-hydroxymethylimidazoles | |
US4291178A (en) | Preparation of ortho-hydroxybenzyl alcohols | |
JPS59222430A (en) | Fluorocyclopropane derivative | |
EP0405928B1 (en) | Process for producing 1,4-dihydroxy-2-arylnaphthoate | |
Bartoli et al. | Stereochemistry of halogenation of nitronate adducts from 4-methoxy-1-nitro-naphthalene and RMgX to 1-halogeno-2-alkyl-4-methoxy-1-nitro-1, 2-dihydronaphthalenes and of subsequent elimination to alkylhalogenonaphthalenes. Crystal structure of a tetrahydronaphthalenone derivative | |
US4365072A (en) | Biphenyl aldehydes | |
CA1284153C (en) | Preparation of alkyl trifluroacetoacetate | |
Kadaba et al. | Convenient Syntheses of m-Anisidine | |
US4175192A (en) | Process for preparing quininone | |
US5241103A (en) | Process for producing 1,4-dihydroxy-2-arylnaphthoate | |
NO802139L (en) | OUTPUT CONNECTIONS FOR PREPARING MORPHINE DERIVATIVES, AND PROCEDURE FOR PREPARING OUTPUT |